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Abstract
Background: Limb-girdle muscular dystrophies are a group of genetically heterogeneous diseases that are
inherited in both autosomal dominant (LGMDD) and autosomal recessive forms (LGMDR), the latter is more
common especially in populations with high consanguineous marriages like Iran. In the present study, we aimed to
investigate the genetic basis of patients who are suspicious of being affected by LGMDR.
DNA samples of 60 families suspected of LGMD were extracted from their whole blood. Four short tandem repeat
(STR) markers for each candidate genes related to LGMD R1 (calpain3 related)- R6 (δ-sarcoglycan-related) were
selected, and all these 24 STRs were applied in two sets of multiplex PCR. After autozygosity mapping, Sanger
sequencing and variant analysis were done. Predicting identified variants’ effect was performed using in-silico tools,
and they were interpreted according to the American College of Medical Genomics and Genetics (ACMG) guideline.
MLPA was used for those patients who had large deletions.
Fresh muscle specimens were taken from subjects and were evaluated using the conventional panel of
histochemical stains.
Results: forty out of sixty families showed homozygote haplotypes in CAPN3, DYSF, SGCA, and SGCB genes. The
exons and intron-exon boundaries of the relevant genes were sequenced and totally 38 mutations including CAPN3
(n = 15), DYSF (n = 9), SGCB (n = 11), and SGCA (n = 3) were identified. Five out of them were novel. The most
prevalent form of LGMDs in our study was calpainopathy followed by sarcoglycanopathy in which beta-
sarcoglycanopathy was the most common form amongst them. Exon 2 deletion in the SGCB gene was the most
frequent mutation in this study.
We also reported evidence of a possible founder effect in families with mutations in DYSF and SGCB genes. We also
detected a large consanguineous family suffered from calpainopathy who showed allelic heterogeneity.
Conclusions: This study can expand our knowledge about the genetic spectrum of LGMD in Iran, and also suggest
the probable founder effects in some Iranian subpopulations which confirming it with more sample size can
facilitate our genetic diagnosis and genetic counseling.
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Background
Limb-girdle muscular dystrophies are a group of genetic-
ally heterogeneous disorders in which mainly the pelvic
and shoulder girdle muscles are progressively involved
[1]. They are inherited in both autosomal dominant
(LGMDD) and autosomal recessive forms (LGMDR), the
latter is more common [2], and is more observed in pop-
ulations with high consanguineous marriages [3].
Twenty-six types of LGMDR have been identified so
far in which LGMDR1 calpain3-related (LGMD2A, calpai-
nopathy), LGMDR2 dysferlin-related (LGMD2B, dysferlino-
pathy1), and sarcoglycanopathies including LGMDR5 γ-
sarcoglycan-related (LGMD2C), LGMDR3 α-sarcoglycan-
related (LGMD2D), LGMDR4 β-sarcoglycan-related
(LGMD2E), and LGMDR6 δ-sarcoglycan-related
(LGMD2F), are the most common kinds of LGMDRs and
are caused by mutations in CAPN3, DYSF, SGCG (γ-sarco-
glycan), SGCA (α-sarcoglycan), SGCB (β-sarcoglycan), and
SGCD (δ-sarcoglycan) genes respectively [4].
Calpain-3 plays an essential role in sarcomere remodel-
ing [5]. It is an enzyme that can be in active or inactive
forms by its proteolytic activity. It can also cleave some
cytoskeletal and myofibrillar proteins [6]. This protein is
encoded by the CAPN3 gene that is located on 15q15.1
and consists of 24 exons [7]. The DYSF gene is located on
2p13.2 and contains 55 exons. Dysferlin is a transmem-
brane protein, which takes part in sarcolemmal resealing,
differentiation and regeneration of muscles, and is in-
volved in stabilizing stress-induced calcium signaling in
the transverse tubule. This protein is mainly expressed in
skeletal muscle, heart, and kidney [8–11]. SGCA gene is
on 17q21, which is composed of 10 exons. SGCB and
SGCG genes located on 4q12 and 13q12, and have 6 and 8
exons, respectively. SGCD gene locus is on 5q33.2 and
consists of 9 exons. In skeletal muscle, these sarcoglycans
compose heterotetramers in the sarcolemma. Sarcoglycans
form dystrophin-glycoprotein complex (DGC) along with
other proteins that connect the muscle fiber cytoskeleton
to the extracellular matrix [12].
Autozygosity Mapping uses the fact that patients who
born from consanguineous marriages probably inherit two
recessive copies of a mutant allele from a common ances-
tor. The purpose of this method is to search for regions
with homozygosity, which can vary from a few to several
megabases in the patient’s DNA. This way will be followed
by identifying the region that carries a mutated gene in-
volved in rare recessive traits [13]. Autozygosity Mapping
is a powerful approach for gene tracking of autosomal re-
cessive diseases in consanguineous families like Iran [14],
and it can be the right choice for gene mapping in hetero-
geneous diseases such as LGMDs.
This study aims to investigate disease-causing mutations
of genes responsible for LGMDR1 calpain3 related- R6 δ-
sarcoglycan-related in 60 families who are suspicious of
being affected by LGMDRs by autozygosity mapping
followed by Sanger sequencing.
Results
Patient population and LGMD diagnosis
We evaluated 60 families for different mutations in our
center. Most affected individuals born to consanguin-
eous marriages and 40 out of 60 families with 112 pa-
tients showed homozygote haplotypes in CAPN3, DYSF,
SGCA, and SGCB genes. Table 1 shows the clinical and
paraclinical features of the available patients.
Mutation analysis
The exons and intron-exon boundaries of the relevant
genes in families whose patients had homozygous haplo-
types were sequenced, and the causative mutations were
found in 38 out of 40 families. Totally 38 mutations were
identified in CAPN3 (n = 15), DYSF (n = 9), SGCB (n = 11),
and SGCA (n = 3). All detected mutations are shown in
Table 1. Five out of 38 mutations were novel (Table 2).
They were evaluated using different software tools such as
DANN, Human Splicing Finder (HSF), Functional Analysis
through Hidden Markov Models (FATHMM), Genomic
Evolutionary Rate Profiling (GERF), and mutation taster.
DANN is a pathogenicity scoring methodology, and it
ranges from 0 to 1, with 1 given to the variants predicted
to be the most damaging. FATHMM is a high-throughput
web-server capable of predicting the functional conse-
quences of coding and non-coding variants. GERP is a con-
servation score, and it ranges from − 12.3 to 6.17. Score
6.17 is the most conserved. All variants’ pathogenicity was
interpreted according to the ACMG guideline (Table 2).
Muscle biopsy studies
Muscle biopsy studies in calpainopathy are not specific
and ranging from mild to severe dystrophic changes. Also
besides, immunohistochemical markers are usually unreli-
able [15].
In dysferlinopathies, almost all fibers are stained with
antibodies against dystrophin 1, 2, and 3, merosin, β-
spectrin, and α, β, and γ sarcoglycans; but the muscle fibers
are looked completely deficient against dysferlin antibody.
In sarcoglycanopathies, labeling with all antibodies except
for sarcoglycans was observed. Table 1 presents the results.
CAPN3
Affected members of 17 out of 60 families showed runs of
homozygosity in the CAPN3 gene, but causative muta-
tions were found in 15 families. All of the families except
for families F11, F7, and F6 had homozygous mutations.
The mentioned families showed compound heterozygous
mutations (Table 1). Eighteen mutations were identified in
our patients, including ten missenses, three splicings, three
deletions, one nonsense, and one deletion/insertion
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mutations. The most frequent mutations were found to be
c.2105C > T and c.380G > A, in which the c.2105C > T
mutation was in the homozygous state in two patients and
compound heterozygous in one patient, and the c.380G >
A mutation detected in homozygous and in compound
heterozygous in one patient.
DYSF
Eight different mutations were found in nine families, in
which two out of them, F20 and F21, who were from
Lurs of Boyer-Ahmad revealed common haplotype and
mutation in the DYSF gene [16]. We identified two dele-
tions, two duplications, two missenses, two nonsenses,
and one splicing mutations in this gene. One of the
mentioned mutations, c.4639-1G > A, which resides in
the intron 42, has not been previously reported. Accord-
ing to the HSF tool, it may alter the wild type acceptor
site and activate an intronic cryptic acceptor site, which
potentially can alter splicing. Its score in other in silico
tools are as shown in Table 2.
SGCA
Three families had homozygous haplotypes in their af-
fected members, and three mutations have been identified
(Table 1), two deletion, and one missense mutations, in
which two out of them were novel (Table 2). The deletion
mutation, c.687-688delTC (p.Leu230Valfs*13), which is a
frameshift one was seen in the homozygous state in the
patient of the family 29 (F29). This mutation resides in the
extracellular domain of the protein.
The other novel mutation was a missense one, chan-
ging amino acid histidine to asparagine in codon 143,
p.His143Asn, which is also located in the extracellular
domain of the protein (Table 2).
SGCB
Eleven families had mutations in the SGCB gene including
two splicing, one duplication, and eight deletion mutations.
Two splicing mutations were not previously reported in
different mutation databases. One of them was c.753 +
1G >A that can disturb wild type donor site of splicing
based on the HSF tool. Another one was c.622-1G > C
which may disrupt the wild type acceptor site of splicing.
The DANN score for both mutations was 0.99, the GERP
score was almost 5, FATHMM results were “damaging”
and mutation taster outcomes were “disease-causing”.
Eight families, F31 to F38, from south-east of Iran showed
the same haplotype and same mutation in the SGCB gene.
The haplotypes are shown in Fig. 1a-e. Performing PCR to
sequence the whole SGCB gene revealed that all exons ex-
cept exon 2 yield amplification products in the affected indi-
viduals. We repeated the PCR of this exon with several
primer pairs, various annealing temperatures, and cycle
numbers, but it did not yield any amplification product
suggesting a possible deletion of this exon. Further analysis
of the patients’ DNA has shown that the multiple primer
sets flanking exon 2 failed to produce PCR product. More
analysis using the MLPA technique confirmed the deletion
of the exon 2, c. (33 + 1_34–1)_(243 + 1_244–1) del, of the
SGCB gene in the patients (Additional file 1 Figure S1, Add-
itional file 2: Figure S2, and Additional file 3: Figure S3). The
mutation results in discarding codon 12 to 81, which leads
to eliminating the large part of the cytoplasmic and trans-
membrane domains of the protein, and this mutation ac-
counts for the most prevalent one in the SGCB gene in our
studied population.
First report of allelic heterogeneity in a consanguineous
LGMD family
Family F7 in this study had eight affected individuals.
Patients V4, V9, and V11 showed homozygous haplo-
types, haplotypes C, for the gene CAPN3, which raise
the possibility of co-segregating of the disease phenotype
with CAPN3 gene. Patients IV5 and IV6 of this family
showed compound heterozygous haplotypes (haplotype
A/C) for this gene (Fig. 2). All 24 exons and exon-intron
boundaries of the CAPN3 gene were sequenced. Patients
V4, V9, and V11 showed the homozygous mutation of
c.1714C > T in exon 13, which was seen in heterozygous
form in patients IV5 and IV6. It raised the possibility of
segregating of this mutation with haplotype C. This mu-
tation caused the substitution of arginine to tryptophan
at residue 572 (Arg572Trp). The other mutation which
was seen in heterozygous form in patients IV5 and IV6,
was c.2311G > A in exon 22, changing alanine to Threo-
nine. This mutation is segregated with haplotype A. Both
mutations were checked in all family members.
Discussion
Prevalence of detected mutations in this study
Due to limited epidemiology data and low incidence of
LGMDs, few reports have been published about the
approximate prevalence of each subtype. In a large co-
hort study in 4656 clinically suspected-LGMD patients
across the US, the diagnosis was established in 27%, in
which calpainopathy and dysferlinopathy were the most
prevalent subtypes [15, 17, 18]. In a study performed on 20
Turkish patients, calpainopathy was the most prevalent
form, and dysferlinopathy was the least form of LGMDs,
and among sarcoglycanopathies, the mutation in the SGCG
gene was the most common and in the SGCA gene was
the least common form [19]. In another study conducted
by Fanin et al, LGMDR1 calpain-3 related was the most
prevalent form in Italian patients, and sarcoglycanopathies
were the second most common type, in which alpha sarco-
glycanopathies were the most frequent forms [20]. A study
on 105 Chinese patients, Showed that the most common
subtype was LGMDR2 dysferlin related, and LGMDR3 α
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-sarcoglycan related is the most frequent type of sarcogly-
canopathies [21]. In research by Okizuka et al., the inci-
dence of LGMDR5 γ -sarcoglycan-related was estimated to
be 1 per 560,000 in the Japanese people [22]. According to
a study by Pathak et al., the most common form of LGMD
in the Indian population was LGMDR1 calpain3-related
[23]. The most common causes of LGMD in Australia
were calpainopathy and dysferlinopathy [24]. Duno et al.
demonstrated that calpainopathy was not a common cause
of LGMD in Denmark [25], and unexpectedly, LGMDR9
FKRP-related had the highest frequency amongall LGMDs
in this country [26]. A study in Iranian affected individuals
with sarcoglycanopathy showed that LGMDR4 β-
sarcoglycan-related (LGMD2E) is the most common form
of sarcoglycanopathies in Iran [2].
In the present study, 38 out of 60 families who were
suspected of being affected by LGMDs had mutation(s)
in CAPN3, DYSF, SGCA, and SGCB genes. The most
prevalent form of LGMDs in our study was calpainopa-
thy followed by sarcoglycanopathy in which beta-
sarcoglycanopathy was the most common form. Exon 2
deletion in the SGCB gene was the most prevalent muta-
tion in this study. Further studies can help us to deter-
mine the frequency of different types of LGMDs and
mutations in the Iranian population.
In spite of observing homozygosity for the CAPN3 gene in
two families of F16 and F17, the causative mutation was not
found. It might be because of incidental finding of homozy-
gosity in these families, or the mutation may reside in deep
intronic sequences or in regulatory elements that are not se-
quenced by Sanger sequencing in the present study.
Evidence of a possible founder effect in our studied
patients
Two unrelated families, F20 and F21, had the same mu-
tation, c.2706dupC, and haplotype for the DYSF gene;
since they had the same ethnicity and were from Lur,
this observation may be suggestive of a possible founder
effect [16]. To our knowledge, this variant has not been
previously reported in Iranian population but it was re-
ported by Cacciottolo et al. in Italy in 2011 [27]. More
sample size is needed to confirm the founder effect.
We also found eight families with the same haplotype
and same mutation. The mutation leads to the deletion of
exon 2. This mutation is a pathogenic one according to the
ACMG guideline and causes elimination of anchor domain
of the SGCB protein which may cause deleterious effect on
the assembly of sarcoglycan complex. The families were
from the south-east of Iran and the Baloch ethnic group. In
another study by Alavi et al., it was shown that almost 85%
(12 out of 14) of their LGMD2E patients had a deletion that
encompassed whole exon 2 in SGCB gene [2]; 10 out of 12
of their studied individuals with this deletion were from
south and south-east of Iran; haplotype analysis based on
three Single nucleotide polymorphisms (SNP) markers
were also suggestive of a possible founder effect in this re-
gion in Iran; and can be beneficial in mutation screening of
the LGMD2 diagnosed patients from this area.
Further studies with more sample size and additional
markers are required to establish a probable founder effect.
Reporting of five novel mutations
We observed a novel deletion mutation of c.687-688delTC
in the SGCA gene, which results in producing a truncated
protein and elimination of downstream part of the protein
including cytoplasmic and transmembrane and some parts
of the extracellular domain of the SGCA protein. Accord-
ing to the ACMG guideline, it is a pathogenic variant.
Another novel mutation, c.427C > A (p.His143Asn), re-
sults in a smaller amino acid, which might lead to loss of
interactions [28]. Segregation analysis in this family has
done in all family members. Since this variant is absent
Table 2 Novel variants observed in our patients
Family Gene
name
Mutation at
DNA level
Mutation at
protein level
Intron/
exon
number
DANN HSF FATHMM GERP Mutation
taster
Zygosity ACMG
interpretation
F24 DYSF c.4639-
1G > A
– 42 0.99 Most probably
affecting
splicing
Damaging 5.36 Disease
causing
Homo Pathogenic (PVS1,
PM2, PP3)
F28 SGCA c.427C > A p.His143Asn 5 0.98 – Damaging 4.3499 Disease
causing
Homo Likely pathogenic
(PS3, PM2, PP3, PP4)
F29 SGCA c.687-
688delTC
p.Leu230Valfs*13 6 – – – 5.1399 Disease
causing
Homo Pathogenic (PVS1,
PM2, PP4)
F39 SGCB c.622-1G >
C
– 5 0.99 Most probably
affecting
splicing
Damaging 5.32 Disease
causing
Homo Pathogenic (PVS1,
PM2, PP3, PP4)
F40 SGCB c.753 +
1G > A
– 5 0.99 Most probably
affecting
splicing
Damaging 5.1199 Disease
causing
Homo Pathogenic (PVS1,
PM2, PP3, PP4)
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from controls in Exome Sequencing Project, 1000 Ge-
nomes Project, or Exome Aggregation Consortium (PM2),
multiple lines of in silico analysis support a deleterious ef-
fect on the gene (PP3), patient’s phenotype is highly spe-
cific for the disease (PP4), and the patient has raised CpK
concentration of about 13,003 (U/L) which it can func-
tionally explain the deleterious effect of the mutation
(PS3); the variant of c.427C >A in SGCA gene is a likely
pathogenic variant.
Two novel mutations which have been observed in
SGCB gene, c.753 + 1G >A and c.622-1G >C, are patho-
genic according to the ACMG interpretation guideline be-
cause null variants like canonical ±1 or 2 splice sites
provide a very strong evidence of pathogenicity for a vari-
ant, the other indications are as follows: PM2, PP3, PP4
which have been described previously.
We detected a mutation in the DYSF gene, c.4639-1G >
A, which has not been previously reported. This mutation
most probably affects splicing and according to the
ACMG guideline is a pathogenic one (PVS1, PM2, PP3).
Unexpected allelic heterogeneity in CAPN3 gene within a
single large consanguineous family
Both observed mutations in the family F7 were previously
reported [29–31] and are likely pathogenic according to
the ACMG guideline (PM1, PM2, PM5, PP3, PP4, PP5 for
c.1714C > T, and PM1, PM2, PP3, PP4 for c.2311G > A).
It’s a general rule that in rare recessive conditions, auto-
zygous mutations are more likely to be causative than com-
pound heterozygous ones [32], but it has been shown that
in highly consanguineous populations, consanguinity has a
powerful effect in the occurrence of many rare diseases
Fig. 1 (a-e): Haplotypes of families with a homozygous deletion of exon 2. STR markers used for the SGCB gene are shown in each figure. Some
markers have not been previously reported and we chose new names for them. U and D mean upstream and downstream respectively. The
numbers denote the distance from the gene (e.g. 8.05 × 105 base pairs)
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than founder effect and it results in allelic heterogeneity
even in genetically isolated populations (or an extended
family) [33]. Locus heterogeneity in LGMD has been previ-
ously reported in a family from Tunis whose two cousins
were affected by LGMDR5 γ -sarcoglycan-related and
LGMDR3 α -sarcoglycan-related in a consanguineous fam-
ily [34]. What we saw in the present study was allelic het-
erogeneity within a highly consanguineous Iranian family
which was the first report of allelic heterogeneity in the
LGMD, and for such a rare disease, it can make us pay
more attention to the difficulty of genetic counseling in in-
bred populations. We have to be more careful about gen-
etic counseling of families with multiple consanguineous
loops when homozygosity in one mutated allele is expected.
Autozygosity mapping in such families can be helpful to
display genetic heterogeneity, both locus and allelic [35].
Conclusion
This study could shed light on the genetic cause of 112
Iranian patients in 38 unrelated families carrying 31 dif-
ferent kinds of mutations. Investigation in other families
is going on. Calpainopathy was the most prevalent sub-
type in our studied sample. We identified five novel
pathogenic variants that enrich human genetic mutation
databases. This study can expand our knowledge about
the genetic spectrum of LGMD in Iran.
Methods
Subjects
Sixty families suspicious of being affected by LGMDs
were referred to Kawsar Human Genetics Research Cen-
ter (KHGRC). Prior to sampling, genetic counseling was
performed, and Informed consent from all families was
obtained. The project was approved by the ethical com-
mittee of the Pasteur Institute of Iran (No: 91/0201/
10425).
Muscle biopsy
Fresh muscle specimens were taken from subjects and
quickly frozen in isopentane cooled by liquid nitrogen. The
specimens were evaluated using the conventional panel of
histochemical stains including H&E, Gomori Modified Tri-
chrome, Congo red, PAS (periodic Acid-Schiff), Oil red O
(ORO), NADH-tetrazolium reductase (NADH-TR), suc-
cinate dehydrogenase (SDH), cytochrome C oxidase
(COX), Modified SDH/COX double stain and ATPase (ad-
enosine triphosphatase) × 3. Immunohistochemical stain-
ing was performed using mouse monoclonal antibodies
against dystrophin (1–3, and), mouse monoclonal anti-
bodies against SGs (α, γ, and β), rabbit monoclonal anti-
bodies against dysferlin, mouse monoclonal antibodies
against β-spectrin, and mouse monoclonal antibodies
against merosin as primary antibody, and HRP-tagged as
Fig. 2 Autozygosity mapping in family P9 which showed allelic heterogeneity. Patients V4, V9 and V11 showed homozygous haplotypes,
haplotypes C. Patients IV5 and IV6 of this family showed compound heterozygous haplotypes (haplotype A/C) for this gene
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the secondary antibody (Novolink, US). Beta-spectrin was
applied as a positive control.
Autozygosity mapping and mutation analysis
Genomic DNA was extracted from peripheral blood using
the salting out procedure (Miller et al. 1988). Four STR
markers for each candidate genes of LGMDR1 calpain3-
related to LGMDR6 δ-sarcoglycan-related were selected
using Map viewer (http://www.ncbi.nlm.nih.gov/projects/
mapview), TRF (http://tandem.bu.edu/trf/trf.html) [36] and
SERV (http://www.igs.cnrsmrs.fr/SERV/) [37] online tools.
These 24 STRs were applied in two sets of multiplex PCR
using Labeled primers. DNA sequencing, interpretation, and
fragment analysis were done as previously described [14].
MLPA
The MLPA test was performed on eight probands using
the SALSA MLPA P116 SGC probe mix (for all sarco-
glycan’s genes) and SALSA MLPA EK1 reagent kit
(MRC Holland-Amsterdam-the Netherland) under the
manufacturer’s protocols [38]. This kit was used in those
patients who their exon 2 amplification of the SGCB
gene fail to produce any product.
In silico analysis
Predicting variant effects on protein structure was per-
formed using six different in-silico tools, including SIFT
[39], CADD [40], Poly Phen-2 [41], HSF [42], PAN-
THER [7], and mutation taster [43]. All variants were
interpreted according to the American College of Med-
ical Genomics and Genetics (ACMG) guideline [44].
Endnotes
1Dysferlinopathy characterized by two principal phe-
notypes including Miyoshi myopathy and LGMD2B
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